王远鹤--吡柔比星用于乳腺癌术后辅助化疗的安全性和有效性..doc

1、安排 《中国肿瘤临床与康复姓名、性别、出生年月，学历，单位具体通讯地址，（什么路，多少号）邮编，邮箱，手机，王远鹤 （作者单位，城市123456） 【摘要目的。方法2011年1月～2012年6月诊治的96例患者随机分成2组：对照组例多柔比星为主的新辅助化疗方案②实验组例吡柔比星为主的新辅助化疗方案。观察结果总率P0.05）；实验组的心脏毒性、脱发的发生率分别为16.67%、39.58%，对照组的心脏毒性、脱发的发生率分别为35.42%、77.08%，实验组的心脏毒性、脱发的发生率明显低于对照组（P0.05）。结论: 吡柔比星化疗he safety and efficacy of neoadjuvant chemotherapy with pirarubicin for breast cancer after surgery（应去掉） Full Name (School or Workplace, City, 123456, China) [Abstract] Objective: To investigate the safety and the clinical efficacy of neoadjuvant chemotherapy with pirarubicin for breast cancer after surgery.（去掉） Methods: The 96 cases of locally advanced breast cancer patients admitted to hospital from January 2011 to June 2012 were randomly divided into two groups, control group (n=48) and treatment group (n=48). The control group was given neoadjuvant chemotherapy with doxorubicin, and the treatment group was given neoadjuvant chemotherapy with pirarubicin.The clinical efficacy and the adverse reactions in 2 groups was observed and compared. Results: The total remission rate for the treatment group and the control group were 81.25%,77.08% ,the clinical efficacy difference was not statistically significant in 2 groups (P0.05); the incidence of cardiotoxicity, alopecia in the treatment group were 16.67%,39.58%,and the incidence of cardiotoxicity, alopecia in the control group were 35.42%,77.08%; the adverse reactions in the treatment group was significantly lower than the control group (P0.05).Conclusion: Neoadjuvant chemotherapy with pirarubicin for locally advanced breast cancer is more safety and reliable. [Key words] Breast cancer; Pirarubicin; Safety; Efficacy 乳腺癌是威胁女性健康的常见恶性肿瘤，neoadjuvant chemotherapy,NCT）是指在恶性肿瘤局部实施手术或放疗前应用的全身性化疗[1]。[2]。目前，临床用于乳腺癌新辅助化疗的药物有很多，如：多柔比星、吡柔比星吡柔比星选择20年月～201年月本院患者例，所有患者经空芯针活检将随机分成2组：①实验组例，年龄~65（44.8±10.7）岁5cm 20例；雌激素受体和（或）孕激素受体阳性32例，全阴性16例；肿瘤患者生存质量Karnofsky评分②对照组例，年龄~68（44.6±10.8）岁5cm 18例；雌激素受体和（或）孕激素受体阳性35例，全阴性13例；Karnofsky评分两组年龄、Karnofsky评分等资料均无显著性差异P0.05），具有可比性。对照组采